Randomized, comparative study of interferon β-1a treatment regimens in MS: The evidence trial

Hillel Panitch, D. S. Goodin, G. Francis, P. Chang, P. K. Coyle, P. O'Connor, E. Monaghan, D. Li, B. Weinshenker

Research output: Contribution to journalArticlepeer-review

556 Scopus citations

Abstract

Background: Interferon β (IFNβ) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial. Methods: This randomized, controlled, multicenter trial compared the efficacy and safety of IFNβ-1a (Rebif®) 44 μg subcutaneously three times weekly (tiw), and IFNβ-1a (Avonex®) 30 μg IM once weekly (qw) in 677 patients with RRMS. Assessors blinded to treatment performed neurologic and MRI evaluations. The primary endpoint was the proportion of patients who were relapse free at 24 weeks; the principal MRI endpoint was the number of active lesions per patient per scan at 24 weeks. Results: After 24 weeks, 74.9% (254/339) of patients receiving IFNβ-1a 44 μg tiw remained relapse free compared with 63.3% (214/338) of those given 30 μg qw. The odds ratio for remaining relapse free was 1.9 (95% CI, 1.3 to 2.6; p = 0.0005) at 24 weeks and 1.5 (95% CI, 1.1 to 2.1; p = 0.009) at 48 weeks, favoring 44 μg tiw. Patients receiving 44 μg tiw had fewer active MRI lesions (p < 0.001 at 24 and 48 weeks) compared with those receiving 30 μg qw. Injection-site reactions were more frequent with 44 μg tiw (83% vs 28%, p < 0.001), as were asymptomatic abnormalities of liver enzymes (18% vs 9%, p = 0.002) and altered leukocyte counts (11% vs 5%, p = 0.003) compared with the 30 μg qw dosage. Neutralizing antibodies developed in 25% of 44 μg tiw patients and in 2% of patients receiving 30 μg qw. Conclusions: IFNβ-1a 44 μg subcutaneously tiw was more effective than IFNβ-1a 30 μg IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.

Original languageEnglish (US)
Pages (from-to)1496-1506
Number of pages11
JournalNeurology
Volume59
Issue number10
DOIs
StatePublished - Nov 26 2002

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Randomized, comparative study of interferon β-1a treatment regimens in MS: The evidence trial'. Together they form a unique fingerprint.

Cite this